ライフサイエンスコーパス: T3

1 T3 caused the highest reduction in survival rate and tru

2 T3 concentrations were increased in tadpoles exposed to

3 T3 is a major regulator of mROS, including hydrogen pero

4 T3 is believed to affect development by regulating targe

5 T3 promoted O4(+) cell differentiation in mouse, but not

6 T3 reduces occupancy of SMAD-binding elements in respons

7 T3+Dex enhanced elementary Ca release measured by Ca spa

8 T3-EO-N(dp) patients had significantly higher intakes of

9 T3-SSB(dp) patients had significantly higher serum phosp

10 final product (T0), and after 1 (T1) and 3 (T3) months of ageing, respectively).

11 et sigma1 of serotype 1 (T1) and serotype 3 (T3) reoviruses.

12 endotype, type 2 (T2) endotype, and type 3 (T3) endotype, respectively.

13 subcutaneous (SC) VRC01 (treatment group 3 [T3], n = 20); placebo (placebo group 3 [P3], n = 4) dose

14 r tumors were associated with higher Ca19.9, T3-T4 and N1, higher grade, perineural invasion, R1 rese

15 5], tumor stage (T1: reference, T2: OR 1.90, T3: OR 2.17), tumor size (<1 cm: reference, 1-2 cm: OR 2

16 expression, and Dot1L in turn functions as a T3 receptor (TR) coactivator to promote vertebrate devel

17 activator (EI-tPA), prior to grafting into a T3 lesion site in a clinically relevant severe SCI model

18 ced metamorphosis and that Dot1L is itself a T3 target gene.

19 ut not neuroblasts, express high levels of a T3-inactivating deiodinase, Dio3.

20 For patients with locally advanced (T3, T4) disease, organ-preservation surgery, combined ch

21 pares the cardiovascular system from adverse T3 action.

22 After T3-SCI, the MCA had more collagen I (42%), collagen III

23 pressures, inward remodelling occurred after T3-SCI with a 40% reduction in distensibility (both P <

24 ring multilamellar vesicles entrapping alpha-T3 resulted in a dramatically improved (by at least 52-f

25 Although T3 is regarded as a maturation factor for cardiomyocytes

26 ), T2 (eosinophilic proteins and CCL26), and T3 (CSF3) endotypic biomarkers in NLF may be able to dis

27 oid cells, and antigen-presenting cells; and T3 CRSsNP was associated with IL-17 signaling, acute inf

28 genome-wide binding of TR in the control and T3-treated tadpole intestine.

29 Multivariable adjusted TSH, FT4 and T3 levels were 25%, 1.3% and 3.9% lower in blacks compar

30 Coordinated glucagon and T3 actions synergize to correct hyperlipidemia, steatohe

31 ynchronized signaling driven by glucagon and T3 reciprocally minimizes the inherent harmful effects o

32 We conclude that hypoxia and T3 enhance the functionality of hESC-VCMs and their engi

33 and two nonenveloped bacteriophages (MS2 and T3) in raw wastewater samples.

34 5.5% (+/-24.5%) for the nonenveloped MS2 and T3, respectively.

35 nduced at T3 target genes during natural and T3-induced metamorphosis and that Dot1L is itself a T3 t

36 me points (T1, ~1 y old; T2, ~2.5 y old; and T3, ~4 y old).

37 Lymphatic spread and T3 stage were predictive of recurrence (univariate, P =

38 until the 3-month vaccination (groups T1 and T3).

39 -free, 3 year cRFS became similar for T2 and T3 cancers.

40 ildren (<6 months at baseline) in the T2 and T3 intervention groups who were fully exposed to the chi

41 Two other trackways (T2 and T3) are designated N. innovatus paratypes characterized

42 different pathways being affected by T2 and T3.

43 o be examined for patients with T1b, T2, and T3 disease, respectively.

44 as not observed when patients were staged as T3, N0 by 8th edition criteria.

45 Median survival in patients staged as T3, N0 by the 7th edition definitions was different betw

46 ASO-T3 enhances white fat browning, decreases genes for fatt

47 Both NNMT-ASO-T3 (NAT3) and ApoB-ASO-T3 (AAT3) enhance thyroid hormone receptor activity.

48 Both NNMT-ASO-T3 (NAT3) and ApoB-ASO-T3 (AAT3) enhance thyroid hormone

49 We hypothesize that ASO-T3 conjugates may knock down target genes and enrich T3

50 At T3 patients representing BT <= 1 mm exhibited a total vo

51 ined 0.28 servings/d higher than baseline at T3 among those who received the intervention.

52 (total) remained significantly different at T3.

53 ted/adjacent teeth displayed GRD increase at T3 (P <0.001).

54 that H3K79 methylation levels are induced at T3 target genes during natural and T3-induced metamorpho

55 rvention group had better quality of life at T3.

56 , respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscale

57 In Drosophila, mimicking phosphorylation at T3 decreased HTTex1 aggregation both in larvae and adult

58 results demonstrate that phosphorylation at T3 stabilizes the alpha-helical conformation of the N-te

59 lysis at T2 whereas 44 patients/120 sites at T3.

60 This difference was sustained at T3 ( P < .001).

61 espite the structural differences, it can be T3-secreted and can nuclear-localize.

62 igen-specific CD8(+) T cells in mice bearing T3 methylcholanthrene-induced sarcomas that are suscepti

63 tional consequences of this variant on brain T3 activity, endoplasmic reticulum stress in glial cells

64 cific antibody inhibited hemagglutination by T3 virions but not ISVPs, indicating that the antibody-

65 e climax of metamorphosis and are induced by T3.

66 e degraded by DNA exonucleases or ligated by T3 and T4 DNA ligases.

67 a cell proliferation in vitro was reduced by T3 in a dose-dependent manner and increased by insulin a

68 d evidence that these genes are regulated by T3 and likely involved in the T3-induced formation of ad

69 96 and 349 genes were uniquely regulated by T3, whereas 22, 40 and 929 were exclusively regulated by

70 ibution and PD-L1 expression was revealed by T3 analysis of the whole tumors.

71 ant in sodium-sulfate (T2), sodium-chloride (T3), sodium-chloride/sulfate (T4), and calcium/magnesium

72 circumstances, only one-fifth of circulating T3 is directly released by the thyroid, but in states of

73 ds of ypN0 was decreased in case of clinical T3 stage (OR 0.59, 95% CI 0.40-0.87), cN1 (OR 0.03, 95%

74 Cluster T3 is similar to cluster T2 in terms of chronic airflow

75 Seven weeks after complete T3 spinal cord transection (T3-SCI, n = 15) or sham inju

76 nonical mechanism of MAPK activation couples T3 actions on mitochondria to cell cycle activation.

77 ds to the TH receptor, whereas DIO3 degrades T3 and T4.

78 Garcinoic acid (GA or delta-T3-13'COOH), is a natural vitamin E metabolite that has

79 bdaLambdaLambda)T3 and (DeltaDeltaDeltaDelta)T3 upon treatment with (R,R)M and (S,S)M, respectively.

80 ambda/R pair), whereas (DeltaDeltaDeltaDelta)T3 favored S-EtB instead of R-EtB (Delta/S pair ratio =

81 ne with T1b disease and another with diffuse T3 disease, underwent secondary enucleation.

82 Liver-directed T3 action offsets the diabetogenic liability of glucagon

83 hat survive through metamorphosis) or during T3-induced metamorphosis.

84 e been studying intestinal remodeling during T3-dependent Xenopus metamorphosis as a model for organ

85 -CM treated with T3+Dex, but not with either T3 or Dex alone, developed an extensive T-tubule network

86 Enhancing T3 signaling in the brain with LT3 improved cognition, w

87 gates may knock down target genes and enrich T3 action in fat and liver.

88 utralizing alphavbeta3 antibodies, excluding T3-induced beta3 messenger RNA, suggesting subspecializa

89 Exogenous T3 stimulates proliferative ERK1/2 signaling in apical c

90 In young adult hearts, exogenous T3 increases cardiomyocyte numbers after DUSP5 depletion

91 Here, we show that exogenous T3 increases the cardiomyocyte endowment of P8 hearts, b

92 But whether exogenous T3 functions as a mitogen in post-P6 murine hearts is no

93 owed by a rapid increase in Mct8 expression (T3/T4 transport), peaking early-September before gradual

94 For selected patients with extensive T3 or large T4a lesions and/or poor pretreatment larynge

95 Plasma free (F) T3 and T4 were measured at baseline, and at 9 days and 1

96 aternal lineage of ancestral male and female T3-overexposed mice revealed, respectively, 1089 and 154

97 ents, and we provide evidence that bona-fide T3 phosphorylation alters Huntingtin exon 1 protein conf

98 Finally, T3 cages have been employed in a host-guest study as the

99 line effect of 0.216 SD [0.043 to 0.389] for T3) and lower stunting prevalence (-9.0% [95% CI -16.7 t

100 o -1.2] for T2 and -8.2% [-15.6 to -0.7] for T3); supplementing mothers conferred no additional benef

101 strate that endogenous Dot1L is critical for T3-induced activation of endogenous TR target genes whil

102 a novel redox pathway that is permissive for T3-mediated cardiomyocyte proliferation-this because of

103 body responses had higher response rates for T3 and T4, respectively.

104 No material difference in risk was seen for T3 or N1 disease.

105 he brain, T4 is converted to the active form T3 by type 2 deiodinase (D2).

106 howed an increased intrinsic ability to form T3 Our data support the hypothesis that TG processing in

107 with an increased intrinsic ability to form T3 upon in vitro iodination.

108 and a GalNAc transferase (polypeptide GalNAc-T3).

109 ally and functionally closely related GalNAc-T3 homolog did not show compensatory functionality for e

110 To test whether D2-generated T3 plays a role in exercise-induced PGC-1a expression, m

111 e vaccines containing the DNA vector (groups T3 and T4).

112 Expression of H2-T3/TL and H2-Q10 is restricted to the small intestine an

113 tions to reduce exposure and improve health (T3).

114 The highest tertile of patients in HF (T3-HF(dp)) pattern significantly associated with higher

115 e-oligonucleotides (ASO) and thyroid hormone T3 conjugates for obesity treatment.

116 t combines glucagon with the thyroid hormone T3 lowers lipid levels, improves glucose tolerance, and

117 However, the thyroid hormone T3 up-regulated mitoIK, ATP, conferring diazoxide protec

118 Here we show that exogenous thyroid hormone (T3) administration increases cardiomyocyte numbers in ne

119 Thyroid hormone (T3) affects development and metabolism in vertebrates.

120 Glucagon and thyroid hormone (T3) exhibit therapeutic potential for metabolic disease

121 es taking place when plasma thyroid hormone (T3) levels are high.

122 iously shown that exogenous thyroid hormone (T3) stimulates cardiomyocyte proliferation in P2 cardiom

123 We have been studying thyroid hormone (T3)-dependent amphibian metamorphosis in two highly rela

124 Here we report that a thyroid hormone (T3)-free window, with or without a demyelinating insult,

125 The host T3 showed certain selectivity toward one enantiomer over

126 not only transform our understanding of how T3 orchestrates adult brain lineage decisions, but also

127 separation was obtained using an Acquity HSS T3 C18 column, with an external calibration curve of exc

128 s subjected to chromatographic analysis (HSS T3 column) and Q-Exactive Orbitrap-MS.

129 us Rhizopus microsporus, bacterial type III (T3) secretion is known to be essential.

130 sed higher levels of inhibitory molecules IL-T3 and PD-L1.

131 children in T0, 500 in T1, 494 in T2, 499 in T3, and 500 in T4) at baseline who were assessed at 1-ye

132 ;2, BoiPIP2;3) were significantly changed in T3 of RNAi plants.

133 Here we investigate morphological changes in T3 hyperthyroid cases in the zebrafish to better underst

134 Dose escalation in T3-T4 tumors did not increase local control.

135 While IgG3 responses were highest in T3, a lower IgA/IgG ratio was observed in T4.

136 were observed in 95%-100% of participants in T3 and T4, two weeks after final vaccination at high mag

137 pling between L-type Ca channels and RyR2 in T3+Dex-treated cells.

138 man ventricular cardiomyocytes, T-tubules in T3+Dex-treated hiPSC-CM were less organized and had more

139 ri-iodothyronine (T3) production or increase T3 degradation preserves cones.

140 injecting suspensions of tri-iodothyronine (T3) in coconut oil into the midbrain ventricle or into t

141 IOs) to suppress cellular tri-iodothyronine (T3) production or increase T3 degradation preserves cone

142 (LambdaLambdaLambdaLambda)T3 preferred R-EtB over S-EtB (75:25) because of better

143 tetrahedral cages (LambdaLambdaLambdaLambda)T3 and (DeltaDeltaDeltaDelta)T3 upon treatment with (R,R

144 after intervention (T2) and 6 months later (T3).

145 ulated in the trans-Golgi and generated less T3, which was restored by eliminating ER stress with the

146 At the practice level (T3), translating evidence into practice remains challeng

147 respectively); while in the hypothyroid, low T3, and low T3T4 groups minimal change disease is now th

148 and never smoking were associated with lower T3 and FT4 levels compared to current smoking.

149 d DNA at M0 and M1 and protein at M3 and M6; T3 received DNA at M0, M1, M3, and M6 with protein coadm

150 While many T3 response genes have been identified in different anim

151 1 month (T1), 4 months (T2), and 12 months (T3) after implant insertion and superimposed with a comp

152 post-therapy (T1), and 3 (T2) and 6 months (T3) later.

153 sodium nitrite; T2: 50 mg of sodium nitrite; T3: 50 mg of sodium nitrite and 0.150 uL/g TP; T4: 50 mg

154 ition, novel data indicated that T4, but not T3, controls integrin's outside-in signaling by phosphor

155 found that upon iodination in vitro, de novo T3 formation in TG was decreased in mice lacking TSHRs.

156 ion substrate in a way that enhances de novo T3 formation, contributing to the relative T3 toxicosis

157 sphorylation contributes to enhanced de novo T3 formation.

158 Conversely, de novo T3 that can be formed upon iodination of TG secreted fro

159 At 5 years, 25% of T3 patients presented with metastasis; overall and speci

160 and malformations provoked by alterations of T3 levels.

161 As an application of T3, 3D mapping and analysis revealed a heterogeneous dis

162 of Dio3 provides double-pronged blockage of T3 action during glial lineage commitment.

163 sensitive to physiological concentrations of T3 , insulin and leptin.

164 Deletion of T3 to T6 produced the smallest construct (delT3-6) exami

165 K9 or K15, reversed the inhibitory effect of T3 phosphorylation.

166 At the end of T3, 83% of the 64 treated sites showed recession reducti

167 with SMAD3 and SMAD4 that is independent of T3-mediated transcriptional activity but requires residu

168 r and inner ring deiodination (O and IRD) of T3 and 3,3'-T2 formation from T4, respectively, with an

169 no influence on the oncological outcomes of T3/T4 rectal cancers.

170 ces gene activation by TR in the presence of T3.

171 n premetamorphic tadpoles in the presence of T3.

172 characteristics, with a lower proportion of T3 and T4 lesions (27.9% v 39.8%), fewer patients with p

173 T1 sigma1, the carbohydrate-binding site of T3 sigma1 is located in the tail domain, distal to the a

174 The sperm of T3-overexposed male ancestors revealed significant hypom

175 ssenger RNA, suggesting subspecialization of T3 and T4 binding to the integrin receptor pocket.

176 P, conferring diazoxide protective effect on T3-treated hESC-VCMs.

177 hesis in liver, and shows limited effects on T3 target genes in heart and muscle.

178 aggregation by regulating phosphorylation on T3.

179 Most patients presented with T2 (37 %) or T3 (29 %) cancer.

180 Patients with TanyN+M0 or T3-4N0M0 LA-SCCHN were randomized 1:1 to receive standar

181 Interventions: Patients with TanyN+M0 or T3-4N0M0 LA-SCCHN were randomized 1:1 to receive standar

182 tion clinical categories T1-T2, N2a-N3 M0 or T3-T4, N0-N3 M0; Zubrod performance status 0 or 1; age a

183 tate but with a positive surgical margin) or T3 (with histologic extension beyond the prostatic capsu

184 cantly different between the groups at T2 or T3.

185 ilapia treated with equimolar doses of T2 or T3.

186 with intermediate-thickness melanomas (T2 or T3; Breslow thickness of > 1.0 to 4.0 mm).

187 ents at a low risk of recurrence (T1, T2, or T3 and N1), either 6 months of adjuvant chemotherapy or

188 rrays of TTAGGG repeats flanked by the T7 or T3 promoters.

189 rs), and at the end of the follow-up period (T3) over 25 to 30 years.

190 rs), and at the end of the follow-up period (T3) over 25 years.

191 Pharmacological T3 treatment increases energy expenditure and causes wei

192 eriod characterized by high levels of plasma T3.

193 rong repression of more than 43% of positive T3 (3,3',5-triiodothyronine) targets in hypothyroid mice

194 effects sustained at 6 mo postintervention (T3).

195 lec or T4lec during ppGalNAc-T2 and ppGalNAc-T3 catalytic reaction had a clear inhibitory effect on G

196 In cells and mice, it blocked ppGalNAc-T3-mediated glycan-masking of FGF23 thereby increasing i

197 a cell-based fluorescence sensor of ppGalNAc-T3 but not on a sensor of ppGalNAc-T2.

198 irectly binds and inhibits purified ppGalNAc-T3 with no detectable activity against either ppGalNAc-T

199 o identify a compound targeting the ppGalNAc-T3 isozyme, we screened libraries to find compounds that

200 invasiveness driven by upregulated ppGalNAc-T3 suggesting the inhibitor might be anti-metastatic.

201 the placebo group and one in the DNA-primed T3 group, had serious adverse events that were judged un

202 f 264 vertebrates shows the long propeptide, T3, T4, T6, and T6a domains have been deleted several ti

203 doses of NYVAC vector and gp120 Env protein; T3 was two doses of DNA vector followed by two doses of

204 04 to 2014 was queried for patients with pT2/T3 gallbladder adenocarcinoma who underwent resection.

205 with trunk diameter and proline leaf ratio (T3/T1) significantly correlated with the exclusion of Na

206 -16.2%, -1.1%; P = 0.03] and VAT:SAT ratio (T3-T1: -0.04; beta: -7.1%; 95% CI: -13.5%, -0.3%; P = 0.

207 A quantitative relationship between reduced T3 and reduced AC inflation was established, a critical

208 phosphorylatable residue in the N17 region (T3, S13 and S16) towards huntingtin exon 1 (HTTex1) olig

209 Rs), patients develop a syndrome of relative T3 toxicosis.

210 o T3 formation, contributing to the relative T3 toxicosis of Graves' disease.

211 Physiologically relevant T3 (1 nM) and T4 (100 nM) concentrations in OVCAR-3 (hig

212 Proteins resembling T3-secreted transcription activator-like (TAL) effectors

213 nal modification (phosphorylation at residue T3) of a protein associated with polyglutamine repeat ex

214 trial in patients with resectable high-risk T3, T4, and/or N2 CC on baseline computed tomography (CT

215 ely associated with overall RT (central, S3, T3, I3, and N3 sectors, P = .004-.024) and the thickness

216 wed undetectable serum T4 and very low serum T3 levels when fed a diet supplying the minimum I(-) req

217 e monotherapy to universally normalize serum T3 levels.

218 advanced invasive breast cancer (tumor size T3/T4), inflammatory breast cancer, or ductal carcinoma

219 s 2 and (2) monosomy 3 and large tumor size (T3-4 by American Joint Committee on Cancer classificatio

220 s. 57%; P < 0.001), had smaller tumor sizes (T3-4 56% vs. 83%; P = 0.001), and were younger.

221 Eligible patients had clinical-stage T3 rectal adenocarcinoma within 12 cm of the anal verge

222 s the proportions with combined tumour stage T3 and T4 remained constant.

223 axillary lymph nodes or primary tumour stage T3-4 disease were eligible to participate.

224 For adults initially with stage T3 HCC who received LRT, there were three studies report

225 .78, 95% CI 9.01-18.12), increasing T Stage (T3 OR 3.36, 95% CI 2.52-4.50, T4 OR 6.30, 95% CI 4.71-8.

226 ricular cardiac micro-tissue (hvCMT) system, T3 substantially enhanced the developed tension by 3-fol

227 s and 18 days of exposure, whereas total (T) T3 and TT4, thyroid histology and hepatic T4-ORD were de

228 ition T0-T3, N0-N2c, M0 (AJCC 8th edition T0-T3, N0-N2, M0), (2) being p16 positive, and (3) reportin

229 nt Committee on Cancer (AJCC) 7th edition T0-T3, N0-N2c, M0 (AJCC 8th edition T0-T3, N0-N2, M0), (2)

230 ion (performance status 0-2, tumour stage T1-T3 with the possibility of lymph-node involvement but no

231 institutions (Gleason scores: 6-9, Stage: T1-T3).

232 pper cervical (C2-C4) and upper thoracic (T1-T3 level) cord.

233 The severe asthma clusters (T2, T3, and T4) had higher sputum eosinophilia than cluster

234 tanks, barrels) and barrel toasting (T1, T2, T3) on ellagitannin concentration, volatile composition

235 re randomized to 4 treatment groups (T1, T2, T3, and T4) and received intramuscular injections at 0,

236 e allocated either active treatment (T1, T2, T3, and T4) or placebo (C1, C2, C3, and C4).

237 mend extended/radical cholecystectomy for T2/T3 gallbladder cancer; however, many tumors are discover

238 rapy prolongs survival after resection of T2/T3 tumors.

239 nd measuring changes in thyroid hormone (T4, T3, rT3, and 3,3'-T2) concentrations.

240 eement with this transcriptional cross-talk, T3 is able to antagonize fibrotic processes in vivo.

241 n the carboxyl-terminal portion of mouse TG, T3 is formed de novo independently of deiodination from

242 We find that T3 phosphorylation is greatly reduced in samples from Hu

243 These suggest that T3 induces Dot1L expression, and Dot1L in turn functions

244 The T3-specific antibody inhibited hemagglutination by T3 vi

245 eanwhile, examination of the leaves from the T3 of RNAi transformants indicated reduction of cell exp

246 One participant in the T3 group died from cranial trauma after a motor vehicle

247 2, and T4 intervention groups and 248 in the T3 intervention group) and 2490 children aged 0-11 month

248 ost-range-determining regions (HRDRs) in the T3 phage tail fiber protein and developed a high-through

249 e regulated by T3 and likely involved in the T3-induced formation of adult intestinal stem cells duri

250 Under the salt stress, the T3 of RNAi plants showed significant higher resistance.

251 Thus, the T3-T6 domains of human ADAMTS13 are dispensable.

252 Using the T3-dependent metamorphosis in Xenopus tropicalis as a mo

253 antly 2.35 times higher (p = 0.005) with the T3-SSB(dp).

254 regions, in which TAL effectors harbor their T3 and nuclear localization signals, and activation doma

255 s to examine the influence of high-thoracic (T3 spinal segment) SCI on cerebrovascular structure and

256 y of patients diagnosed as having T1 through T3 M0 pancreatic adenocarcinoma between January 1, 2004,

257 regulating target gene transcription through T3 receptors (TRs).

258 idues Tyr(5) and Tyr(130), whereas thyroidal T3 production may originate in several different ways.

259 L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is overexpressed in ovarian cancer.

260 he cervical and upper thoracic cord (down to T3 level) was calculated with the active-surface method.

261 e same cells are differentially sensitive to T3 at different time points.

262 ity phase 3 trial of 475 patients with T1 to T3 rectal adenocarcinoma <15 cm from anal verge, given L

263 ients with clinical-radiographic stage T1 to T3, N0 to N3, and M0 NSCLC who underwent endobronchial u

264 adjacent untreated teeth improved from T2 to T3 (P <0.001).

265 The accelerated conversion of T4 to T3 within myocytes mediates part of the PGC-1a induction

266 hibition of Dio mediated conversion of T4 to T3.

267 tion of peripheral deiodinase-mediated T4-to-T3 conversion provided a physiologic means to justify l-

268 e we describe transparent tissue tomography (T3) as a tool for rapid, three-dimensional, multiplexed

269 s after complete T3 spinal cord transection (T3-SCI, n = 15) or sham injury (Sham, n = 10), rats were

270 f thyroxine (T4) to 3,5,3'-triiodothyronine (T3) and may not be optimal in some cases when based on T

271 Although 3,5,3'-triiodothyronine (T3) is considered to be the primary bioactive thyroid ho

272 pression and plasma 3,3',5-triiodothyronine (T3) concentrations in tadpoles treated at higher tempera

273 ebrates: thyroxin (T4) and triiodothyronine (T3), making the zebrafish a very useful model to study h

274 in both thyroxine (T4) and triiodothyronine (T3), were the first pharmacologic treatments available a

275 icals decreased whole body triiodothyronine (T3) concentrations, either through inhibition of thyroxi

276 w that the thyroid hormone triiodothyronine (T3), through binding to its nuclear receptors (TRs), is

277 The effects of triiodothyronine (T3 ), insulin and leptin on beta cell proliferation rate

278 utcome had lower levels of triiodothyronine (T3) and higher thyroxine (T4).

279 ed serum concentrations of triiodothyronine (T3), free thyroxine (FT4), thyroid peroxidase antibody (

280 dothyronine (T4), and some triiodothyronine (T3).

281 converts thyroxine (T4) to triiodothyronine (T3), which binds to the TH receptor, whereas DIO3 degrad

282 ngly associated with total triiodothyronine (T3), free T4, or thyroid-stimulating hormone (TSH).

283 y response to vaccination, triiodothyronine (T3), hepatic biotransformation (7-ethoxyresorufin-O-deet

284 ssion when initiated in the third trimester (T3).

285 PDX) engraftment in locally advanced tumors (T3-T4 or N+) predict poor prognosis in patients with bla

286 ocarcinoma within 12 cm from the anal verge, T3/4 and/or node positive, were randomly assigned to 5 w

287 ents were stratified by T category (T1-T2 vs T3-T4), N category (N0-N2a vs N2b-N3), Zubrod performanc

288 es were present in 19% of cases and 23% were T3 lesions.

289 gnalling and transcriptional pathways, while T3 regulated pathways related to cell signalling, the im

290 -based organic phosphate (p < 0.001), whilst T3-SSB(dp) patients had significantly higher intakes of

291 nt and tumor characteristics: 263 (80%) with T3 or T4 disease, 215 (66%) N1, and 62 (19%) with celiac

292 ight loss were significantly associated with T3/T4 disease.

293 and ApoB-ASO are chemically conjugated with T3 using a non-cleavable sulfo-SMCC linker.

294 e, consecutive cohort study of patients with T3-4 choroidal melanomas according to the 7th edition of

295 Patients with T3-T4 tumors underwent a second random assignment 1:1 be

296 cal differentiation method supplemented with T3 (triiodothyronine) and/or Dex (dexamethasone) during

297 hiPSC-CM treated with T3+Dex, but not with either T3 or Dex alone, developed a

298 metamorphic tadpoles treated with or without T3 and for chromatin immunoprecipitation assays with the

299 T2 plus LNS for pregnant or lactating women (T3); or T1 plus fortnightly home visits to promote and e

300 end of the follow-up period (18 to 35 years, T3).